FDA grants accelerated approval to Clovis' ovarian cancer drug

Clovis Oncology on Monday earned accelerated approval from the Food and Drug Administration for its ovarian cancer drug Rubracam, reports Reuters.

Rubraca is intended for advanced ovarian cancer patients with a BRCA gene mutation who have already been treated with two or more chemotherapies.

The FDA also approved on Monday a diagnostic test to identify the presence of BRCA gene mutations, which was designed to be used in tandem with Rubraca, according to the report.

The FDA's Accelerated Approval Program allows for the earlier approval of drugs to fill an unmet clinical need, according to the agency's website. The continued approval of Rubraca is contingent on the results of two clinical trials Clovis Oncology must conduct to confirm the drug's efficacy.

More articles on supply chain:

Amazon looking to develop 'Uber' for truck shipments
5 supply chain strategies to control hospital drug spending
FDA removes mental health warning from Pfizer's anti-smoking drug

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars